Abstract 264P
Background
Cancer-related cognitive impairment (CRCI), affecting up to 80% of breast cancer (BC) patients, manifests in various cognitive domains such as learning, memory, and concentration. The hippocampus, crucial for these cognitive processes and known to retain its neurogenesis capacity throughout adulthood, is susceptible to morphological alterations due to BC treatment. Recent research highlights the link between physical exercise and neurogenesis. This study aims to investigate CRCI and the potential effects of high-intensity interval training (HIIT) on learning, memory, and concentration function, as well as brain morphology in BC patients undergoing treatment.
Methods
This randomized (1:1) controlled trial allocated early-stage BC patients to either a HIIT intervention group (IG) or a control group (CG). The intervention involved a 12-month supervised HIIT program tailored through cardio-pulmonary exercise testing. Learning, memory, and concentration function were assessed using the California Verbal Learning Test (CVLT) alongside the Wechsler Memory Scale (WMS). Hippocampal volume was evaluated with MRI-based free surfer analysis. Assessments were conducted at baseline and after 12 months.
Results
A total of 69 patients (mean age 50.67 years, SD 10.55; 98.5% female) were recruited. The analysis showed no statistically significant changes in total hippocampal volume in either group (IG: p = 0.25 and p = 0.39; CG: p = 0.25 and p = 0.33). Similarly, no significant changes were observed in the CVLT scores for both groups (IG: p = 0.102; CG: p = 0.059). However, compared to the CG, the IG exhibited significant improvements in the WMS (p < 0.05).
Conclusions
Assessing CRCI in BC patients is challenging. Despite a multimodal approach, we couldn't objectify structural or functional adverse effects on specific cognitive subdomains. Although HIIT exercise during chemotherapy didn't notably impact learning and memory, it did enhance concentration over time. This might suggest that cognitive function in BC patients benefits from exercising.
Clinical trial identification
NCT04789187. Registered on 09 March 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Verein zur Forschungsförderung der Krebshilfe OÖ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
312P - Early detection of metastatic disease in asymptomatic early-stage breast cancer patients using imaging: A cross-sectional analytic study at a tertiary hospital
Presenter: John kelvin Lalusis
Session: Poster session 14
313P - A longitudinal follow-up study on the prognosis of patients with breast cancer with delayed diagnosis during the COVID-19 pandemic
Presenter: Jae Pak Yi
Session: Poster session 14
314P - The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients
Presenter: Mark Magbanua
Session: Poster session 14
315P - Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer
Presenter: Oscar Danielsson
Session: Poster session 14
316P - Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials
Presenter: Magdalena Rios Romero
Session: Poster session 14
317TiP - A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer
Presenter: Zhimin Shao
Session: Poster session 14
318TiP - Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study
Presenter: Fleur Louis
Session: Poster session 14
319TiP - NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
Presenter: Etienne Bastien
Session: Poster session 14
321P - Sentinel lymph node biopsy in clinical T3-4c breast cancer: A retrospective multicenter cohort study
Presenter: Yasuaki Sagara
Session: Poster session 14
322P - Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Presenter: Alexandra Thomas
Session: Poster session 14